Biodexa Bolsters Management Team: Dr. Gary A. Shangold Appointed as Chief Medical Officer
Wednesday, Jan 22, 2025 8:49 am ET
2min read Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, has strengthened its management team with the appointment of Dr. Gary A. Shangold as Chief Medical Officer, effective immediately. This strategic move comes as Biodexa prepares for later clinical stages, including an upcoming global Phase 3 registrational study in Familial Adenomatous Polyposis (FAP).
Dr. Shangold brings extensive experience across all phases of drug development in multiple therapeutic areas, having served in various leadership roles at companies such as Enteris BioPharma, Xanodyne Pharmaceuticals, and NovaDel Pharma. His expertise in regulatory affairs, particularly at Johnson & Johnson's R.W. Johnson Pharmaceutical Research Institute, will be invaluable in guiding Biodexa through the complex regulatory landscape as it advances its pipeline, including eRapa, tolimidone, and MTX110.
eRapa, Biodexa's lead development program, is a proprietary oral tablet formulation of rapamycin (sirolimus), an mTOR inhibitor under development for FAP and Non-Muscle Invasive Bladder Cancer. Dr. Shangold's experience in securing two New Drug Applications (NDAs) at Xanodyne Pharmaceuticals demonstrates his ability to successfully navigate the regulatory process, which will be crucial for eRapa's approval.
Tolimidone, another key asset in Biodexa's pipeline, is an orally delivered, potent and selective inhibitor of Lyn kinase, under development for the treatment of type 1 diabetes. Dr. Shangold's background in diabetes and metabolic disorders, particularly his role as President & CEO of NovaDel Pharma, will be beneficial in the development and testing of tolimidone as a potential first-in-class blood glucose modulating agent.
MTX110, Biodexa's third pipeline asset, is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat, being studied in aggressive rare/orphan brain cancer indications. Dr. Shangold's experience as Chief Medical Officer at Enteris BioPharma, a company focused on developing innovative drug formulations, will be relevant in the development and optimization of MTX110's convection-enhanced delivery (CED) method, which aims to bypass the blood-brain barrier and potentially avoid systemic toxicity.
Dr. Shangold's leadership and expertise will be crucial in helping Biodexa navigate the later clinical stages, including the upcoming global Phase 3 registrational study in FAP, and potentially secure regulatory approvals. His proven track record in securing regulatory approvals, managing Phase 3 studies, and making strategic decisions will be invaluable in guiding Biodexa through the challenges and opportunities that lie ahead.
In conclusion, Biodexa Pharmaceuticals' appointment of Dr. Gary A. Shangold as Chief Medical Officer is a strategic move that strengthens the company's management team and positions it for success in the later clinical stages. Dr. Shangold's extensive experience in drug development, regulatory affairs, and diabetes, coupled with his proven track record, makes him an invaluable addition to Biodexa's team as they advance their pipeline of innovative products.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
